Compare Occidental Petroleum Corporation (OXY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Occidental Petroleum Corporation trades at $60.5 (market cap $60.26B), while State Street SPDR S&P Biotech ETF trades at $150.56 (market cap $10.11B). The key difference: Occidental Petroleum Corporation is far larger — about 6× State Street SPDR S&P Biotech ETF's market cap, and Occidental Petroleum Corporation pays a 1.86% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Occidental Petroleum Corporation for 92 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| OXY | XBI | |
|---|---|---|
Market Cap | $60.26B | $10.11B |
Volume | 11,718,920 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $66.24 | $169.55 |
52-Week Low | $38.92 | $104.99 |
Typical Hold Time | 92 Days | 37 Days |
Enterprise Value | $79.02B | — |
Dividend Yield | 1.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $58.21, showing slight daily weakness but maintaining a bullish technical trend with strong fundamental metrics. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $2.40 significantly exceeding the $1.83 forecast. Valuation remains attractive with a P/E of 17.78 and EV/EBITDA of 5.56, while profitability metrics show robust margins and returns.
OXY presents compelling value with analyst consensus price target of $71.40 representing 23% upside potential. The company's debt reduction progress and strong cash flow generation support dividend sustainability. Key risks include oil price volatility and execution challenges in carbon management initiatives. Wall Street sentiment remains positive with 52% buy ratings among analysts.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
